SCHEMBL4051222

SCHEMBL4051222

FC(F)(F)Oc1cccc(C=Cc2nc3cc(-c4ccccc4)ccc3o2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KMT2A Q03164 2/20 0.56
HPGD P15428 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
USP30 Q70CQ3 1/20 0.45
CHEK1 O14757 1/20 0.45
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
UTRN P46939 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
ATR Q13535 1/20 0.39
DHODH Q02127 1/20 0.37
P2RY14 Q15391 2/20 0.37
FAAH O00519 1/20 0.37
CETP P11597 1/20 0.37
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4051217 1.00 MEN1 (0.56) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4053353 0.85 ALDH1A1 (0.41) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4053351 0.85 ALDH1A1 (0.41) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4059220 0.84 UTRN (0.39) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4059215 0.84 UTRN (0.39) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4052719 0.82 SMN1; SMN2 (0.65) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4052714 0.82 SMN1; SMN2 (0.65) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4050352 0.82 MEN1 (0.59) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4050354 0.82 MEN1 (0.59) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL4053426 0.78 MEN1 (0.58) MEN1ALDH1A1KMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B MEN1 3709/4885ALDH1A1 3683/4885KMT2A 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.